The US FDA Approves Exablate Neuro Platform for Treating Parkinson’s Disease
19 july 2025
Last February, the Vattikuti Foundation entered into an agreement with the All India Institute of Medical Sciences in New Delhi to collaborate on the treatment of neurological diseases by using the Insightec Exablate Neuro system using High Intensity Focused Ultrasound (HIFU). Previously, the device had received clearance for trials to treat Essential Tremors.
Here is a portion of what Insightec CEO and Chairman Maurice R.Ferre, MD recently posted on LinkedIn:
"Today is a historic day for Insightec and the millions living with Parkinson’s disease. The FDA has approved our Exablate Neuro platform for staged bilateral treatment of Parkinson’s disease (pallidothalamic tractotomy, or PTT), marking an important step forward in the advancement of MR-guided focused ultrasound for movement disorders.
This milestone offers physicians a new option to manage disabling motor symptoms without incisions, implants, or traditional surgery. It reflects the dedication of our team, the passion of our clinical partners, and the trust of the patients we serve."
Vattikuti Foundation CEO Dr. Mahendra Bhandari responded:
"Congrats Maurice R.! 🎉yet another milestone."
